Cannabis Science, Inc. (OTCBB:CBIS.ob - News), a pioneering US biotech company whose mission is to alleviate suffering and promote health through cannabinoid science, is pleased to announce that Dr. Robert Melamede, President and CEO, is scheduled to speak at the Patients Out of Time 7th National Clinical Conference on Cannabis Therapeutics.
A schedule and full list of speakers can be reviewed on the Patients Out of Time website at www.medicalcannabis.com. Aside from Dr. Melamede and Dr. Courtney, speakers will include prominent doctors and scientists from around the world. Another highlight of the weekend is the Saturday panel entitled "The ECS and Clinical Implications for Health Care" including Clint Werner (Moderator), Andrew Weil, MD, and Julie Holland, MD, Melanie Dreher, RN, PhD.
The event includes addresses from Patients Out of Time founders Al Byrne and Mary Lynn, as well as appearances from 2 of the 4 federal medical cannabis patients Elvy Musikka and Irv Rosenfeld. Complete interviews with all 4 federal patients are available through Kaneabis (a Cannabis Science company) at www.kaneabis.com by subscribing for the free newsletter.
Friday and Saturday's conference topics include Cannabis and its benefits with cancer; post traumatic stress disorder (PTSD), glaucoma, schizophrenia, stress, anxiety, Alzheimer's, and a wide range of other medical cannabis topics.
The unique benefit of the Patients Out of Time Conference on cannabis therapeutics is its accreditation by The University of California's San Francisco School of Medicine (UCSF), which in turn is accredited by the Accreditation Council for Continuing Medical Education. UCSF designates this educational activity for a maximum of 12.75 AMA PRA Category 1 credits.
Contact hours are provided by the University of Arizona Medical Center Staff Development and Education, which is approved by The California Board of Registered Nursing, BRN Provider No. CEP 10039 (hours pending).
The event will host a Patients Out of Time benefit dinner sponsored by Cannabis Science, which includes music by Greta Gaines from her upcoming album "Grassy Girl;" a live and silent auction, and a guest appearance by Gigi Ganjay. Greta's information may be found at www.gretagaines.com, www.cannibuzz.com, and http://www.conlincasting.net/Gretareel/Greta_Gaines/Reel.html Greta Gaines is a client of Kaneabis (a Cannabis Science company).
Portions of the event will be available via Pay Per View for only $9.99/day. For more details in regards to Pay Per View please visit http://www.ustream.tv/channel/patients-out-of-time
This event follows several other events in which Cannabis Science has been involved, including the successful opening of "Chronic Future: Killing Cancer." Details can be viewed at http://finance.yahoo.com/news/cannabis-science-reports-first-documentary-180300497.html
Dr. Melamede has additional scheduled appearances at both the Cannabis Revival Film Festival (April 16-18th in Denver, Colorado) and the "High Times" Medical Cannabis Cup in Denver from April 21-22.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
www.cannabisscience.com
Contacts:
Cannabis Science, Inc.
Robert Kane, 561.234.6929
Vice
President of Investor Relations
rkane@cannabisscience.com
or
Dr.
Robert Melamede, President
info@cannabisscience.com
